Profound Medical PROF Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Profound Medical in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: Profound Medical’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Profound Medical's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Profound Medical's cash & equivalents?
- Profound Medical (PROF) reported cash & equivalents of $50.3M in Q1 2026.
- How has Profound Medical's cash & equivalents changed year-over-year?
- Profound Medical's cash & equivalents increased by 8.3% year-over-year, from $46.43M to $50.3M.
- What is the long-term trend for Profound Medical's cash & equivalents?
- Over 2 years (2023 to 2025), Profound Medical's cash & equivalents has grown at a 50.9% compound annual growth rate (CAGR), from $26.21M to $59.72M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.